DR REDDYS LABORATORIES LTD — Regulatory Filings 2021

Jun 15, 2021

==> picture [468 x 113] intentionally omitted <==

June 15, 2021

Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai – 400 001 Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039

National Stock Exchange of India Ltd. “Exchange Plaza” Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 Fax Nos.: 022-26598120/ 26598237/ 26598238

Scrip Code: 500124

- Scrip Code: DRREDDY EQ

Dear Sirs,

Sub: Intimation

This is to inform you about the receipt of an arbitration award issued by the International Center for Dispute Resolution, U.S., whereby a subsidiary of Dr. Reddy’s Laboratories Limited (the Company) has been asked to pay an amount of US$46.25 mn (towards milestones, interest and fees) to Hatchtech Pty Ltd., in relation to the asset purchase agreement entered into between the parties in 2015.

On July 27, 2020 the Company had announced the receipt of an approval of XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA by the U.S. Food and Drug Administration (USFDA). Such approval triggered the contractual pre-commercialization milestone of US$20 mn payable to Hatchtech Pty Ltd. which is included in the above mentioned award and has already been accounted for and charged off in the Company’s financial statements for the financial year 2020-21.

The Company is exploring all legal options to challenge the award.

This is for your information and records.

With regards,

Digitally signed by SANDEEP PODDAR DN: c=IN, o=Personal, pseudonym=5baa65b04542ac0f9e3878c9d91f0 SANDEEP db36d0548a0, 2.5.4.20=bfda99c592e4dc5b7a2e12970b9505d 6d51634ab609953e7b6cd73ea7af49394, postalCode=500084, st=TELANGANA, serialNumber=8185d5106ea0d6196f14ae660c0 PODDAR 9bac334f5ebc1a1790e158f29af33bf208cac, cn=SANDEEP PODDAR Date: 2021.06.15 20:38:04 +05'30'

Sandeep Poddar Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd